Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;18:91-7.
doi: 10.1016/j.coph.2014.09.008. Epub 2014 Sep 29.

Discovery and Development of New Antibacterial Agents Targeting Gram-negative Bacteria in the Era of Pandrug Resistance: Is the Future Promising?

Affiliations
Review

Discovery and Development of New Antibacterial Agents Targeting Gram-negative Bacteria in the Era of Pandrug Resistance: Is the Future Promising?

Malcolm G P Page et al. Curr Opin Pharmacol. .

Abstract

Multidrug-resistant Gram-negative bacteria continue to pose a threat, with many infections caused by these pathogens being virtually untreatable. A number of new antibacterial agents are in late stage clinical development to treat these infections. Drugs in known classes such as new quinolones, aminoglycosides, tetracyclines, and β-lactams have been designed to evade many of the known resistance mechanisms, whereas newer drug classes include novel β-lactamase inhibitors in combination with new or approved β-lactams, and a peptidomimetic that have entered full clinical development. The establishment of public-private partnerships and an increase in pharmaceutical interest in antibacterial R&D are encouraging signs for the future.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

MeSH terms

Substances

LinkOut - more resources

Feedback